Related Experiment Video

Updated: Aug 29, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

[Diagnosis and misdiagnosis of adrenoleukodystrophy: a causal analysis]

Yan Huang1, Xiu-qin Liu

  • 1Department of Neurology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China. huangyan90@hotmail.com

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
|January 13, 2004
PubMed

Insights

Adrenoleukodystrophy (ALD) diagnosis is often delayed due to unfamiliarity with its symptoms. Early detection of ALD is possible through very long-chain fatty acid testing.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Adrenoleukodystrophy (ALD) is a rare genetic disorder affecting the adrenal glands and white matter of the brain.
  • ALD is characterized by the accumulation of very long-chain fatty acids (VLCFAs) in tissues.

Observation:

  • This study analyzed six cases of ALD, including childhood cerebral ALD, Addison-only disease, and adolescent cerebral ALD.
  • Skin pigmentation was an initial symptom in three cases, with diagnostic delays ranging from 1 to 6 years for Addison's disease.
  • Two cases were initially misdiagnosed as multiple sclerosis.

Findings:

  • Physician unfamiliarity with ALD's diverse clinical presentations is a primary cause of diagnostic delay.
  • Assessing very long-chain fatty acids (VLCFAs) is crucial for the early and accurate diagnosis of ALD.

Implications:

  • Improved physician education on ALD symptoms can reduce diagnostic delays.
  • Early VLCFA testing can facilitate timely intervention and management of ALD patients.
Abstract

More Related Videos

A Visual Approach for Inducing Dolichoectasia in Mice to Model Large Vessel-Mediated Cerebrovascular Dysfunction04:29

A Visual Approach for Inducing Dolichoectasia in Mice to Model Large Vessel-Mediated Cerebrovascular Dysfunction

Published on: May 17, 2024

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...